LIFEMD INC (LFMD) Stock Fundamental Analysis
USA - NASDAQ:LFMD - US53216B1044 - Common Stock
6.15 USD
-0.02 (-0.32%)
6.15 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to LFMD. LFMD was compared to 35 industry peers in the Health Care Technology industry. LFMD may be in some trouble as it scores bad on both profitability and health. LFMD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year LFMD has reported negative net income.
In the past year LFMD had a positive cash flow from operations.
LFMD had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: LFMD reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of LFMD (-12.28%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.28% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-86.73%
ROA(5y)-171.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LFMD's Gross Margin of 87.57% is amongst the best of the industry. LFMD outperforms 94.29% of its industry peers.
In the last couple of years the Gross Margin of LFMD has grown nicely.
LFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y3.8%
2. Health
2.1 Basic Checks
LFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LFMD has more shares outstanding
LFMD has more shares outstanding than it did 5 years ago.
LFMD has a better debt/assets ratio than last year.
2.2 Solvency
LFMD has an Altman-Z score of 0.68. This is a bad value and indicates that LFMD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.68, LFMD is in line with its industry, outperforming 51.43% of the companies in the same industry.
The Debt to FCF ratio of LFMD is 2.31, which is a good value as it means it would take LFMD, 2.31 years of fcf income to pay off all of its debts.
LFMD's Debt to FCF ratio of 2.31 is fine compared to the rest of the industry. LFMD outperforms 77.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.31 | ||
| Altman-Z | 0.68 |
ROIC/WACCN/A
WACC10.2%
2.3 Liquidity
LFMD has a Current Ratio of 0.77. This is a bad value and indicates that LFMD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.77, LFMD is doing worse than 80.00% of the companies in the same industry.
LFMD has a Quick Ratio of 0.77. This is a bad value and indicates that LFMD is not financially healthy enough and could expect problems in meeting its short term obligations.
LFMD's Quick ratio of 0.72 is on the low side compared to the rest of the industry. LFMD is outperformed by 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.00% over the past year.
Looking at the last year, LFMD shows a very strong growth in Revenue. The Revenue has grown by 37.74%.
Measured over the past years, LFMD shows a very strong growth in Revenue. The Revenue has been growing by 76.23% on average per year.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.42%
Revenue 1Y (TTM)37.74%
Revenue growth 3Y31.75%
Revenue growth 5Y76.23%
Sales Q2Q%22.81%
3.2 Future
Based on estimates for the next years, LFMD will show a very strong growth in Earnings Per Share. The EPS will grow by 40.83% on average per year.
The Revenue is expected to grow by 19.29% on average over the next years. This is quite good.
EPS Next Y74.18%
EPS Next 2Y56.23%
EPS Next 3Y40.83%
EPS Next 5YN/A
Revenue Next Year23.06%
Revenue Next 2Y20.2%
Revenue Next 3Y19.29%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LFMD. In the last year negative earnings were reported.
LFMD is valuated quite expensively with a Price/Forward Earnings ratio of 25.84.
LFMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LFMD is cheaper than 71.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of LFMD to the average of the S&P500 Index (23.23), we can say LFMD is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.84 |
4.2 Price Multiples
LFMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LFMD is cheaper than 68.57% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LFMD indicates a somewhat cheap valuation: LFMD is cheaper than 65.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.34 | ||
| EV/EBITDA | 30.07 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as LFMD's earnings are expected to grow with 40.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.23%
EPS Next 3Y40.83%
5. Dividend
5.1 Amount
No dividends for LFMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.15
-0.02 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners53.98%
Inst Owner Change0.11%
Ins Owners18.82%
Ins Owner Change2.51%
Market Cap277.00M
Revenue(TTM)245.56M
Net Income(TTM)-9034000
Analysts81.33
Price Target13.13 (113.5%)
Short Float %13.63%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-34.38%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-258.37%
Min EPS beat(2)-635.29%
Max EPS beat(2)118.55%
EPS beat(4)2
Avg EPS beat(4)-117.63%
Min EPS beat(4)-635.29%
Max EPS beat(4)118.55%
EPS beat(8)3
Avg EPS beat(8)-68.88%
EPS beat(12)5
Avg EPS beat(12)-64.04%
EPS beat(16)6
Avg EPS beat(16)-52.91%
Revenue beat(2)1
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-8.06%
Max Revenue beat(2)2.97%
Revenue beat(4)2
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-8.06%
Max Revenue beat(4)9.78%
Revenue beat(8)5
Avg Revenue beat(8)1.81%
Revenue beat(12)7
Avg Revenue beat(12)-0.1%
Revenue beat(16)7
Avg Revenue beat(16)-1.47%
PT rev (1m)0%
PT rev (3m)-8.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-89.82%
EPS NY rev (3m)-859.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.84 | ||
| P/S | 1.13 | ||
| P/FCF | 41.34 | ||
| P/OCF | 14.22 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.07 |
EPS(TTM)-0.21
EYN/A
EPS(NY)0.24
Fwd EY3.87%
FCF(TTM)0.15
FCFY2.42%
OCF(TTM)0.43
OCFY7.03%
SpS5.45
BVpS-0.04
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.28% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.57% | ||
| FCFM | 2.73% |
ROA(3y)-86.73%
ROA(5y)-171.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y3.8%
F-Score5
Asset Turnover3.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.31 | ||
| Debt/EBITDA | 0.41 | ||
| Cap/Depr | 120.74% | ||
| Cap/Sales | 5.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 227.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 0.68 |
F-Score5
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)162.46%
Cap/Depr(5y)195.18%
Cap/Sales(3y)6.18%
Cap/Sales(5y)4.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.42%
EPS Next Y74.18%
EPS Next 2Y56.23%
EPS Next 3Y40.83%
EPS Next 5YN/A
Revenue 1Y (TTM)37.74%
Revenue growth 3Y31.75%
Revenue growth 5Y76.23%
Sales Q2Q%22.81%
Revenue Next Year23.06%
Revenue Next 2Y20.2%
Revenue Next 3Y19.29%
Revenue Next 5YN/A
EBIT growth 1Y89.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year254.54%
EBIT Next 3Y69.78%
EBIT Next 5YN/A
FCF growth 1Y162.68%
FCF growth 3YN/A
FCF growth 5Y88.7%
OCF growth 1Y816.14%
OCF growth 3YN/A
OCF growth 5Y133.93%